EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.
about
CIViC databaseBiological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cellsCandidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cellsAnti-EGFR-Conjugated Hollow Gold Nanospheres Enhance Radiocytotoxic Targeting of Cervical Cancer at Megavoltage Radiation EnergiesEpidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.KRAS and MAPK1 gene amplification in type II ovarian carcinomas.HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER InhibitorsOncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.Dihydroartemisinin induces apoptosis of cervical cancer cells via upregulation of RKIP and downregulation of bcl-2Management of advanced or recurrent cervical cancer: chemotherapy and beyond.Signaling pathways in HPV-associated cancers and therapeutic implications.Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma.Somatic Host Cell Alterations in HPV Carcinogenesis.let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer.Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.
P2860
Q27612411-DCA7B816-14D9-4805-8EE0-92658AFE4C17Q33925336-47E49A31-1471-4987-AA67-ACF54DBD0A6DQ33933054-DA4EE2EE-05B7-41DD-8563-D40DD4200BAAQ34533633-2D195C9E-6F59-4CC0-AFBB-7CBCFDEA7884Q35625307-0AC4BE5B-E916-4C9F-9E71-8F112ACB9C37Q35885555-577C3F93-743C-4A2E-A5A0-E3780BAE3314Q36082772-71618D83-BB58-4F61-8A62-E8EDB6E45DCEQ37091859-43F3FCA3-9F11-449E-9550-718BB18C81B2Q37668572-44AC7A49-9BF8-417D-8A10-406C4AFD540BQ37678092-A01C9E5A-2FCE-4764-995C-63879134DA2AQ37683039-2004DBD5-DACC-4391-BF17-039C9205822EQ38178742-AE017FBA-CD00-44E9-A8CD-FAE009659892Q38370778-0A6F415E-5335-4BCA-B9E4-EACFEB0AA115Q40092876-638C9E52-4D9E-4129-9F1A-5706C0623B9FQ40096622-1BCF4E18-E956-49F5-AF77-C7773FE5E17EQ54985726-508E930F-85FB-43AA-9626-28C12960F9F3Q55028849-A8F3F760-B6C6-4230-A9D9-0FC3FED1BDE5
P2860
EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@ast
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@en
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@nl
type
label
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@ast
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@en
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@nl
altLabel
EGFR gene amplification is rel ...... way a novel therapeutic target
@en
prefLabel
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@ast
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@en
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@nl
P2093
P2860
P3181
P356
P1476
EGFR gene amplification is rel ...... ay a novel therapeutic target.
@en
P2093
A Katagiri
H Kobayashi
K Miyazaki
K Nakayama
M Ishikawa
M T Rahman
S Nakayama
P2860
P2888
P3181
P356
10.1038/BJC.2011.222
P407
P577
2011-07-26T00:00:00Z
P5875
P6179
1011266574